Terminal complement pathway activation drives synaptic loss in Alzheimer’s disease modelsSarah M. Carpanini, B. Paul Morgan|Acta Neuropathologica Communications|2022Cited by 97
The complement system in neurodegenerative diseasesJacqui Nimmo, B. Paul Morgan, Sarah M. Carpanini et al.|Clinical Science|2024Cited by 48
The schizophrenia-associated gene CSMD1 encodes a complement classical pathway inhibitor predominantly expressed by astrocytes and at synapses in mice and humansRobert A.J. Byrne, B. Paul Morgan, Jacqui Nimmo et al.|Brain Behavior and Immunity|2025Cited by 11
119 Characterising complement in amyloid-beta plaquesLewis M. Watkins, B. Paul Morgan, Megan Torvell et al.|Immunobiology|2023Cited by 0